Enovis (STU:C520) Change In Receivables : €-14 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Enovis Change In Receivables?

Enovis's change in receivables for the quarter that ended in Mar. 2024 was €-11 Mil. It means Enovis's Accounts Receivable increased by €11 Mil from Dec. 2023 to Mar. 2024 .

Enovis's change in receivables for the fiscal year that ended in Dec. 2023 was €-15 Mil. It means Enovis's Accounts Receivable increased by €15 Mil from Dec. 2022 to Dec. 2023 .

Enovis's Accounts Receivable for the quarter that ended in Mar. 2024 was €351 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Enovis's Days Sales Outstanding for the three months ended in Mar. 2024 was 67.35.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Enovis's liquidation value for the three months ended in Mar. 2024 was €-1,401 Mil.

Enovis Change In Receivables Historical Data

The historical data trend for Enovis's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enovis Change In Receivables Chart

Enovis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

44.93

35.09

-98.22

-42.66

-14.96

Enovis Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-11.48	-12.58	18.16	-8.98	-11.05

Enovis Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14 Mil.

Enovis (STU:C520) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Enovis's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	350.569	/	474.965	*	91
=	67.35

2. In Ben Graham's calculation of liquidation value, Enovis's accounts receivable are only considered to be worth 75% of book value:

Enovis's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	60.966	-	1994.412	+	0.75 * 350.569	+	0.5 * 539.122
=	-1,401

Enovis Change In Receivables Related Terms

Thank you for viewing the detailed overview of Enovis's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Enovis (STU:C520) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Enovis Corp (STU:C520) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ENOV:USA

Address

2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808

Website

https://www.enovis.com

Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy.. The company conducts its operations through two operating segments: Prevention & Recovery ("P&R") and Reconstructive ("Recon"). It generates majority revenue form Prevention & Recovery segment.

Enovis (STU:C520) Headlines

No Headlines